drugset / Trial / NCT02114502
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if carfilzomib and vorinostat combined with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control multiple myeloma (MM). Researchers also want to learn about the safety and effectiveness of this combination.
Timeline
- Start
- 2014-09
- Primary completion
- 2018-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 27 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1875 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 60 mg/m2 | Intravenous |
| Subject | SAHA | Unknown | 1000 mg | Oral |
| Background | Caphosol | Other / unclassified | 30 ml | Oral |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Background | Glutamine | Other / unclassified | 15 g | Oral |
| Background | Palifermin | Protein / enzyme biologic | 60 ug/kg | Intravenous |
| Background | Pyridoxine | Unknown | 100 mg | Intravenous |